Pfenex And Alvogen Forsteo Biosimilars Primed For EU Market

As Accord Announces Withdrawal Of MAA

Shortly after announcing the launch of Bonsity (teriparatide) in the US, Pfenex and Alvogen have picked up positive opinions from the EMA’s CHMP for their teriparatide biosimilar. However, Accord Healthcare has withdrawn its own application following concerns raised by the agency.

EUFlags3
Pfenex And Alvogen's Teriparatide Biosimilar May Debut In The EU Soon • Source: Shutterstock

Two biosimilar Forsteo (teriparatide) rivals belonging to Pfenex and Alvogen have been recommended for pan-European marketing authorizations by the European Medicines Agency’s Committee for Medicinal Products for Human Use, at the same time as Accord Healthcare announced it was pulling its application for the osteoporosis treatment over bioequivalence study data concerns.

Applications filed by Theramex Ireland under the Livogiva name and Alvogen’s EuroGenerics Holdings business domiciled in the Netherlands under the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.